Bicycle Therapeutics plc (NASDAQ:BCYC) went up by 22.52% from its latest closing price compared to the recent 1-year high of $22.71. The company’s stock price has collected -1.05% of loss in the last five trading sessions. Press Release reported 3 hours ago that Bicycle Therapeutics Announces Pipeline Progress Update
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Is It Worth Investing in Bicycle Therapeutics plc (NASDAQ :BCYC) Right Now?
Opinions of the stock are interesting as 8 analysts out of 8 who provided ratings for Bicycle Therapeutics plc declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $27.75, which is $3.43 above the current price. BCYC currently public float of 4.33M and currently shorts hold a 7.19% ratio of that float. Today, the average trading volume of BCYC was 53.99K shares.
BCYC’s Market Performance
BCYC stocks went down by -1.05% for the week, with a monthly jump of 2.32% and a quarterly performance of 4.42%, while its annual performance rate touched 80.62%. The volatility ratio for the week stands at 3.10% while the volatility levels for the past 30 days are set at 4.85% for Bicycle Therapeutics plc. The simple moving average for the period of the last 20 days is 25.52% for BCYC stocks with a simple moving average of 38.73% for the last 200 days.
Analysts’ Opinion of BCYC
Many brokerage firms have already submitted their reports for BCYC stocks, with Cantor Fitzgerald repeating the rating for BCYC by listing it as a “Overweight.” The predicted price for BCYC in the upcoming period, according to Cantor Fitzgerald is $30 based on the research report published on October 12th of the previous year 2020.
H.C. Wainwright gave a rating of “Buy” to BCYC, setting the target price at $25 in the report published on April 17th of the previous year.
BCYC Trading at 24.51% from the 50-Day Moving Average
After a stumble in the market that brought BCYC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 7.10% of gains for the given period.
Volatility was left at 4.85%, however, over the last 30 days, the volatility rate increased by 3.10%, as shares surge +25.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.49% upper at present.
During the last 5 trading sessions, BCYC rose by +20.73%, which changed the moving average for the period of 200-days by +74.95% in comparison to the 20-day moving average, which settled at $19.62. In addition, Bicycle Therapeutics plc saw 10.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCYC starting from Kalowski Lee, who sale 7,500 shares at the price of $22.50 back on Dec 01. After this action, Kalowski Lee now owns 0 shares of Bicycle Therapeutics plc, valued at $168,750 using the latest closing price.
Kalowski Lee, the President and CFO of Bicycle Therapeutics plc, sale 530 shares at $20.00 during a trade that took place back on Nov 27, which means that Kalowski Lee is holding 0 shares at $10,600 based on the most recent closing price.
Stock Fundamentals for BCYC
Current profitability levels for the company are sitting at:
- -188.38 for the present operating margin
The net margin for Bicycle Therapeutics plc stands at -221.78. The total capital return value is set at -35.41, while invested capital returns managed to touch -41.87. Equity return is now at value -42.70, with -28.80 for asset returns.
Based on Bicycle Therapeutics plc (BCYC), the company’s capital structure generated 2.03 points at debt to equity in total, while total debt to capital is 1.99. Total debt to assets is 1.72, with long-term debt to equity ratio resting at 1.34. Finally, the long-term debt to capital ratio is 1.32.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
When we switch over and look at the enterprise to sales, we see a ratio of 11.47, with the company’s debt to enterprise value settled at 0.14. The receivables turnover for the company is 1.50 and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.81.
